Statements (80)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
gptkb:Roche
|
| gptkbp:campusFacilities |
gptkb:Children's_Hospital_of_Philadelphia
|
| gptkbp:CEO |
gptkb:Jeffrey_D._Marrazzo
|
| gptkbp:clinicalTrials |
ongoing
Phase 3 |
| gptkbp:collaborations |
gptkb:Bristol-Myers_Squibb
Novartis |
| gptkbp:focus |
gene therapy
|
| gptkbp:founded |
2013
|
| gptkbp:founder |
gptkb:Jeffrey_D._Marrazzo
|
| gptkbp:headquarters |
gptkb:Philadelphia,_Pennsylvania
|
| https://www.w3.org/2000/01/rdf-schema#label |
Spark Therapeutics
|
| gptkbp:investmentFocus |
venture capital firms
|
| gptkbp:keyPeople |
gptkb:Katherine_A._High
|
| gptkbp:mission |
transforming the lives of patients with genetic diseases.
|
| gptkbp:notableEvent |
gptkb:Luxturna
|
| gptkbp:partnerships |
gptkb:University_of_Pennsylvania
|
| gptkbp:products |
gptkb:SPK-9001
gptkb:SPK-7001 gptkb:SPK-3001 gptkb:SPK-1001 therapeutics SPK-3002 SPK-3003 SPK-3004 SPK-3005 SPK-3006 SPK-3007 SPK-3008 SPK-3009 SPK-3010 SPK-3011 SPK-3012 SPK-3013 SPK-3014 SPK-3015 SPK-3016 SPK-3017 SPK-3018 SPK-3019 SPK-3020 SPK-3021 SPK-3022 SPK-3023 SPK-3024 SPK-3025 SPK-3026 SPK-3027 SPK-3028 SPK-3029 SPK-3030 SPK-3031 SPK-3032 SPK-3033 SPK-3034 SPK-3035 SPK-3036 SPK-3037 SPK-3038 SPK-3039 SPK-3040 SPK-3041 SPK-3042 SPK-3043 SPK-3044 SPK-3045 SPK-3046 SPK-3047 SPK-3048 SPK-3049 SPK-3050 SPK-8011 |
| gptkbp:region |
global
|
| gptkbp:regulatoryCompliance |
FDA_approval_for_Luxturna
|
| gptkbp:research_focus |
rare genetic diseases
|
| gptkbp:sells |
gptkb:NASDAQ
|
| gptkbp:technology |
AAV_vector_technology
|
| gptkbp:type |
public company
|
| gptkbp:website |
www.sparktx.com
|